Candel Therapeutics, Inc. (CADL) Market Cap & Valuation Ratios
Candel Therapeutics, Inc. (CADL) has a market cap of $614.4M and a price-to-sales ratio of 4955.2, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CADLCandel Therapeutics, Inc.Follow CADL — free
—
Price chart with a free account
- Market cap
- 614.4M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| CADL | 0.6 | — | — | — | -9.3% | — | — | — |
| AURA | 0.7 | — | — | — | — | — | — | -88% |
| DSGN | 0.6 | — | — | — | -8.6% | — | — | -42% |
| SLDB | 0.6 | — | — | — | — | — | — | -127% |
| LXRX | 0.6 | — | 11.9 | — | -10.3% | -29% | -131% | -30% |
| WVE | 0.6 | — | 4.0 | — | — | -30% | -333% | -255% |
| CRMD | 0.6 | 3.8 | 1.1 | 2.0 | — | +281% | 47% | 57% |
| SGMT | 0.6 | — | — | — | -7.0% | — | — | -59% |
| CLYM | 0.6 | — | — | — | -9.3% | — | — | -36% |
| IMMX | 0.6 | — | — | — | -6.7% | — | — | — |
| ZVRA | 0.6 | 10.7 | 2.7 | 4.3 | 5.6% | +119% | 61% | 68% |
| Median of these 10 | 7.2 | 3.3 | 3.1 | -7.8% | +45% | -42% | -42% |
.
Growth vs. price
each dot a company · hover or tap for valuesCandel Therapeutics, Inc. — questions
- What is Candel Therapeutics, Inc.'s market cap?
- $614.4M.
- What is Candel Therapeutics, Inc.'s price-to-sales ratio?
- 4955.2.
Every figure on this page comes from Candel Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.